 |
32 Diseases |  |
1 Trial |
|
1 Trial |  |
313 News |  |
| «123 |
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) (clinicaltrials.gov) - Nov 26, 2013
P3, N=64, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting
- |||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment open: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (clinicaltrials.gov) - May 27, 2013
P3, N=800, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (clinicaltrials.gov) - May 21, 2013
P3, N=800, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) (clinicaltrials.gov) - Apr 24, 2013
P3, N=45, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) (clinicaltrials.gov) - Apr 2, 2013
P3, N=64, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | anacetrapib (MK-0859) / Merck (MSD)
Trial termination: MK0859 Dose-Ranging Study (0859-003) (clinicaltrials.gov) - Mar 31, 2013
P2, N=500, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Completed --> Terminated
- |||||||||| anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) (clinicaltrials.gov) - Jan 2, 2013
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) (clinicaltrials.gov) - Oct 28, 2012
P3, N=450, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- anacetrapib (MK-0859) / Merck (MSD)
Enrollment change: Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) (clinicaltrials.gov) - Feb 29, 2012
P1, N=24, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated N=48 --> 24
- |||||||||| anacetrapib (MK-0859) / Merck (MSD)
New P3 trial: REALIZE: Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (clinicaltrials.gov) - Jan 30, 2012
P3, N=306, Completed, Sponsor: Merck Sharp & Dohme Corp.
- | anacetrapib (MK-0859) / Merck (MSD)
Trial completion: The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3) (clinicaltrials.gov) - Sep 8, 2011
P1, N=46, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=48 --> 24 Active, not recruiting --> Completed